Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
Exact Sciences, Mayo Clinic share early data on esophageal cancer test
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
3 Growth Stocks to Buy at 52-Week Lows in March
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
Exact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the company
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
Guardant posts data for colon cancer blood test amid push from rivals
Cathie Wood Darling Exact Sciences Rises On Highly Anticipated Colon Cancer News
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.